City
Epaper

WHO chief 'glad' to see Covaxin get WHO approval for emergency use

By ANI | Published: November 03, 2021 7:56 PM

Director-General of the World Health Organisation Tedros Adhanom Ghebreyesus on Wednesday said that he was glad to see Hyderabad-based Bharat Biotech's COVID-19 vaccine, Covaxin, get WHO approval for Emergency Use Listing (EUL).

Open in App

Director-General of the World Health Organisation Tedros Adhanom Ghebreyesus on Wednesday said that he was glad to see Hyderabad-based Bharat Biotech's COVID-19 vaccine, Covaxin, get WHO approval for Emergency Use Listing (EUL).

"Glad to see one more vaccine, #Covaxin, being granted @WHO emergency use listing. The more products we have to fight #COVID19, the better, but we must keep up the pressure to deliver #VaccinEquity & prioritize access to vulnerable groups who are still waiting for their 1st dose," Ghebreyesus tweeted.

The WHO granted emergency use listing for India's indigenous vaccine Covaxin, adding to a growing portfolio of vaccines validated by the world health body for prevention of COVID-19.

The WHO said in a tweet that the Technical Advisory Group, convened by World Health Organisation (WHO), has determined that the Hyderabad-based Bharat Biotech's COVID-19 vaccine meets WHO standards for protection against COVID-19.

"WHO has granted emergency use listing (EUL) to COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19," WHO said in a tweet.

"The Technical Advisory Group, convened by WHO and made up of regulatory experts from around the world, has determined that the Covaxin vaccine meets WHO standards for protection against #COVID19, that the benefit of the vaccine far outweighs risks and the vaccine can be used," it added.

The global health body said that the Covaxin vaccine was also reviewed by WHO's Strategic Advisory Group of Experts on Immunization (SAGE), and recommended the use of this vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above.

"Available data on vaccination of pregnant women with the Covaxin vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned, including a pregnancy sub-study and a pregnancy registry," WHO said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: World Health OrganizationBharat biotechBharat biotech limitedBharat biotech international ltdBharat biotech companyBharat biotech internationalBharat biotech biotech
Open in App

Related Stories

NationalCovaxin-Developer Bharat Biotech Amid Reports on AstraZeneca Vaccine, Says ‘Safety Is Primary Focus for All Our Vaccines’

InternationalWHO formally labels artificial sweetener aspartame a 'possible carcinogen'

BusinessMake AI in India: Government, Startups, and Doctors Unite to Build a More Patient-Centric Healthcare System

National"Digital health is very important now...": Bharat Biotech Executive Chairman Dr Krishna Ella at G20 Health Working Group Meet

Health'Even deadlier': WHO chief cautions world over next pandemic

International Realted Stories

InternationalPakistan: Islamabad court reserves verdict in 'un-Islamic' nikah case against Imran Khan, Bushra Bibi

InternationalPakistan: OGRA bans sale, purchase of substandard LPG cylinders

InternationalExplosion in Tanzanian sugar factory claims 11 lives

InternationalPoGB politician raises concern over sale of forest land to Punjab industrialists

InternationalMyanmar seizes over 1,600 tons of illegal teak timber in April-May